Human IL-21 Protein, premium grade
分子別名(Synonym)
IL21,Za11,Interleukin-21
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-21, premium grade (IL1-H5213) is expressed from human 293 cells (HEK293). It contains AA Gln 30 - Ser 162 (Accession # Q9HBE4-1).
Predicted N-terminus: Gln 30
重組人IL-21,premium級(IL1-H5213),專為臨床前階段設(shè)計,具有與GMP級重組人IL-21(GMP-L21H25)相同的活性和性能,可實(shí)現(xiàn)從臨床前開發(fā)到臨床階段的無縫過渡。在原材料安全不是首要任務(wù)的早期開發(fā)階段,premium級產(chǎn)品為GMP級產(chǎn)品提供了一種經(jīng)濟(jì)高效的替代品。通過在早期開發(fā)階段使用Premium級產(chǎn)品,您可以輕松過渡到臨床和商業(yè)階段,而無需重新驗(yàn)證原材料和修改制造工藝。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 15.5 kDa. The protein migrates as 16 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留(Host Cell Protein)
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素-21(IL-21)是一種分泌蛋白,屬于IL-15/IL-21家族。白細(xì)胞介素-21/IL-21屬于細(xì)胞因子家族,與由私人受體(IL21R)和常見細(xì)胞因子受體γ鏈(γ(C))組成的復(fù)合受體結(jié)合。白細(xì)胞介素-21/IL-21影響多種細(xì)胞類型,包括CD8+記憶T細(xì)胞、NK細(xì)胞和CD4記憶T細(xì)胞亞群。IL-21R廣泛分布于淋巴造血細(xì)胞上。IL-21是CD4+T細(xì)胞在抗原刺激下產(chǎn)生的多效性細(xì)胞因子。它的作用通常會增強(qiáng)免疫細(xì)胞的抗原特異性反應(yīng)。IL-21促進(jìn)CD8+T細(xì)胞和NK細(xì)胞的抗腫瘤活性。IL-21通過與特定的I型細(xì)胞因子受體IL-21R結(jié)合發(fā)揮其作用,IL-21R還含有在其他細(xì)胞因子受體中發(fā)現(xiàn)的γ鏈(γc),包括IL-2、IL-4、IL-7、IL-9和IL-15。IL-21/IL-21R相互作用觸發(fā)一系列事件,包括酪氨酸激酶JAK1和JAK3的激活,隨后是轉(zhuǎn)錄因子STAT1和STAT3的激活。
關(guān)鍵字: IL-21;IL-21蛋白;IL-21重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。